Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 19

Showing 19 citing articles:

BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
New strategies to enhance the efficiency and precision of drug discovery
Qi An, Liang Huang, Chuan Wang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Targeted degradation of membrane and extracellular proteins with LYTACs
Yuyang Li, Yang Yang, Renshuai Zhang, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 8
Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)
Zhaoyong Kang, Li Shen, Yan Li, et al.
Chinese Chemical Letters (2024), pp. 110447-110447
Closed Access | Times Cited: 5
DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting
Shiqing Li, Tao Zeng, Zhixing Wu, et al.
Journal of the American Chemical Society (2025)
Closed Access
New pathway under light: conversion of furans to pyrroles
Yue-Liu-Ting Fu, Jun-Wei Shi, Peng Chen, et al.
Science Bulletin (2025)
Closed Access
PROTACs coupled with oligonucleotides to tackle the undruggable
Guangshuai Zhang, Si Yan, Yan Liu, et al.
Bioanalysis (2025), pp. 1-16
Closed Access
Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy
Yanping Zhao, Junhui Sui, Jian Chang, et al.
Nano Today (2025) Vol. 62, pp. 102693-102693
Closed Access
Advancing Head and Neck Cancer Therapies: From Conventional Treatments to Emerging Strategies
Aleksandra Mordzińska-Rak, Ilona Telejko, Grzegorz Adamczuk, et al.
Biomedicines (2025) Vol. 13, Iss. 5, pp. 1046-1046
Open Access
Recent advances in degraders engaging lysosomal pathways and related nanomedicine
Runxin Lu, Xiaofeng Ni, Sha Diao, et al.
European Journal of Medicinal Chemistry (2025), pp. 117701-117701
Closed Access
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Design, Synthesis, and Biological Evaluation of RSL3-based GPX4 Degraders with Hydrophobic Tags
Yao Ning, Zeqi Zhu, Yi‐Cheng Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116719-116719
Closed Access | Times Cited: 3
Posttranslational modifications of E2F family members in the physiological state and in cancer: Roles, mechanisms and therapeutic targets
Mingyang Sun, Yitong Ji, Guo‐Jun Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117147-117147
Open Access | Times Cited: 2
The application of PROTACs in immune-inflammation diseases
Chao Zhang, Xiuyun Sun, Peilu Song, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 115, pp. 117967-117967
Closed Access | Times Cited: 1
Integrative proteogenomic and pharmacological landscape of acute myeloid leukaemia
Hanlin Wang, Jun‐Yu Xu, Tao Wang, et al.
Science Bulletin (2024)
Closed Access | Times Cited: 1
Structure-Based Design of “Head-to-Tail” Macrocyclic PROTACs
Chungen Li, Yihan Chen, Weixue Huang, et al.
JACS Au (2024) Vol. 4, Iss. 12, pp. 4866-4882
Open Access | Times Cited: 1
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Yiyang Li, Yike Wu, Shugeng Gao, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 116-144
Closed Access | Times Cited: 1
DNA Nanotechnology for Application in Targeted Protein Degradation
Yang Xiao, Xinyi Guo, Weiwei Zhang, et al.
ACS Biomaterials Science & Engineering (2024) Vol. 10, Iss. 11, pp. 6814-6827
Closed Access
Design, Synthesis, and Activity Evaluation of BRD4 PROTAC Based on Alkenyl Oxindole-DCAF11 Pair
Man Zhao, Wenjing Ma, Jimmy T. Liang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 19428-19447
Closed Access
Modular Assembly of Heterotrifunctional Molecules Enabled by Iodosulfonylation of Allenes and Subsequent Amination
Xiaofeng Lin, Peng Cao, Shijie Liu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Page 1

Scroll to top